
Bioorganic and Medicinal Chemistry Letters p. 853 - 856 (1999)
Update date:2022-08-05
Topics:
Vince, Robert
Brownell, Jay
Akella, Lakshmi B.
The inhibition of glyoxalase I enzyme to increase cellular levels of methylglyoxal has been developed as a rationale for the production of anticancer agents. Synthesis of a peptidomimetic analog of the previously prepared potent glyoxalase inhibitor, S-(p-bromobenzyl)glutathione (PBBG), was accomplished by inserting a urea linkage, NH-CO-NH, to replace the γ- glutamyl peptide bond. Thus, the target compound, γ-(L-γ-azaglutamyl)-S- (p-bromobenzyl)-L-cysteinylglycine 6, was a potent inhibitor of glyoxalase I with almost no loss of activity when compared to PBBG. However, unlike PBBG, 6 was completely resistant to enzymatic degradation by kidney homogenate or by purified γ-glutamyltranspeptidase enzyme.
View MoreForsman Scientific(Beijing)co.,Ltd.
Contact:+86-10-64646565
Address:Rm No.1301, Building-2, No. A-13 Beiyuan Road, Chaoyang District Beijing, China, PR,
Huzhou City Linghu Xinwang Chemical Co.,Ltd.
Contact:86-572-3948695/3945236
Address:huzhou
Contact:+86-717-6370352
Address:168 Chengdong Avenue, Yichang, Hubei 443003, P. R.China
Hubei Lansun Biochemical Pharmaceutical Co., Ltd
Contact:714-6395977
Address:No. 81 Pengcheng Avenue, economic and technological development zone, Huangshi City, Hubei Province,China
Nanjing Capatue Chemical Co., Ltd
Contact:+86-25-86371192 +86-025-85720158
Address:No.20 Jiangjun Avenue, Jiangning Economic & Technical Development Zone
Doi:10.1016/j.tet.2013.10.024
(2013)Doi:10.1055/s-2001-18706
(2001)Doi:10.1016/S0022-328X(00)86348-2
(1968)Doi:10.1021/ic50075a007
(1969)Doi:10.1016/S0040-4039(01)88000-X
(1969)Doi:10.1021/om990023q
(1999)